← Back to Clinical Trials
Recruiting NCT06104371

NCT06104371 Lymph Node Identification Using Magtrace and Magseed Before Chemotherapy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06104371
Status Recruiting
Phase
Sponsor Vastra Gotaland Region
Condition Breast Cancer
Study Type OBSERVATIONAL
Enrollment 459 participants
Start Date 2025-09-01
Primary Completion 2027-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 85 Years
Study Type OBSERVATIONAL
Interventions
Magtrace

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 459 participants in total. It began in 2025-09-01 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Magnetic tracer injected before preoperative chemotherapy in breast cancer patients for sentinel lymph node detection. Also, magnetic tracer in combination with magnetic clip for index node identification.

Eligibility Criteria

Inclusion criteria: * Patients 18 years of age or older. * Patients with breast cancer planned to undergo NACT with * planned sentinel lymph node dissection (SLND), or * targeted axillary lymph node dissection (TAD), in conjunction with the * breast surgery after NACT. Exclusion Criteria: * Intolerance / hypersensitivity to iron or dextran compounds or SPIO. * Patients who are required to undergo MRI to evaluate tumour response. * Pregnancy or breast feedin.g * Patients with an iron overload disease. * Patient deprived of liberty or under guardianship. * Inability to understand given information and give informed consent or undergo study procedure

Contact & Investigator

Central Contact

Fredrik AM Warnberg, prof

✉ fredrik.warnberg@vgregion.se

📞 +46706146251

Frequently Asked Questions

Who can join the NCT06104371 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06104371 currently recruiting?

Yes, NCT06104371 is actively recruiting participants. Contact the research team at fredrik.warnberg@vgregion.se for enrollment information.

Where is the NCT06104371 trial being conducted?

This trial is being conducted at Gothenburg, Sweden.

Who is sponsoring the NCT06104371 clinical trial?

NCT06104371 is sponsored by Vastra Gotaland Region. The trial plans to enroll 459 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology